BioNTech, the German biotech that partnered with Pfizer to develop the first COVID-19 vaccine to earn the FDA’s emergency use authorization, is now using mRNA to tackle another disease: malaria. The ...

BioNTech aims to develop the first mRNA-based vaccine for Malaria prevention based on a novel multi-antigen vaccine approach First evaluated candidate BNT165b1 expresses certain parts of the ...

BioNTech SE (NASDAQ:BNTX) said on Tuesday, that the U.S. Food and Drug Administration informed of a clinical hold on the company's Investigational New Drug application and mid-stage trial evaluating ...

MAINZ, Germany/OSLO, Norway, May 29, 2024 – BioNTech SE (Nasdaq: BNTX, “BioNTech”, “the Company”) and the Coalition for Epidemic Preparedness Innovations (“CEPI”) are expanding their strategic ...

Up to €95 million in blended EIB and EC financing will help BioNTech advance its mRNA manufacturing site in Kigali, Rwanda.The project aims to strengthen Africa’s ability to produce investigational or ...

The FDA placed a clinical hold on BioNTech’s Phase 1/2a trial for its investigational RNA-based malaria vaccine, BNT165e. BioNTech paused the study and is working with the FDA to address its requests ...

Backed by the eradicateMalaria initiative, German company BioNTech announces a malaria project consisting of the development of an mRNA-based vaccine against the disease and the evaluation of mRNA ...

The European Investment Bank (EIB) and the European Commission will provide a blended financing package worth up to €95 million ($110 million) to BioNTech for its mRNA vaccine factory in Kigali. • The ...

BioNTech SE BNTX will release its fourth-quarter financial results before the opening bell on Monday, March 10. Analysts expect the Mainz, Germany-based company to report quarterly earnings at 25 ...